MARTIN H INFELD
Pharmacy in Montclair, NJ

5393765, Feb 28, 1995

Dec 13, 1993

8/166123

Martin H. Infeld - Upper Montclair NJ
A. Waseem Malick - Edison NJ
Navnit H. Shah - Clifton NJ
Wantanee Phuapradit - Kearny NJ

Hoffmann-La Roche Inc. - Nutley NJ

A61K 31425, A61K 4700, A61K 920

514365

An erodible pharmaceutical composition providing a unique zero order controlled release profile is herein described. The erodible composition contains a therapeutically active substance having a solubility not greater than 80 mg/mL, a hydroxypropyl methylcellulose derivative and erosion modifiers depending on drug solubility and drug loading, such as lactose and polyoxyalkylene derivatives of propylene glycol, as well as other inert materials such as binders and lubricants. The hydroxypropyl methylcellulose derivative is most preferably a hydroxy-propylmethyl having a methoxy content of about 19-30% and hydroxypropyl content of 7-12%, a methoxy degree of substitution from 1. 1 to 2. 0, a molecular weight of approximately 20,000 to 26,000 daltons and a viscosity of a 2% w/w polymer solution at 25. degree. C. ranging from 50 to 100 cps.

2007004, Mar 1, 2007

Aug 3, 2006

11/498445

Hashim Ahmed - Princeton NJ, US
Lewis Bender - Redding CT, US
Martin Infeld - Upper Montclair NJ, US
Shingai Majuru - Brewster NY, US
Wantanee Phuapradit - Montville NJ, US
Navnit Shah - Clifton NJ, US
Zhongshui Yu - Williston Park NY, US

A61K 31/675, A61K 31/663

514089000, 514102000

The present invention provides novel solid pharmaceutical dosage forms for oral administration comprising a bisphosphonate, or a pharmaceutically acceptable salt thereof, which bisphosphonate is present in an amount not therapeutically effective when the bisphosphonate is orally administered alone; and a modified amino acid carrier, or a pharmaceutically acceptable salt thereof, which modified amino acid carrier is present in an amount effective to facilitate absorption of the bisphosphonate in the gastrointestinal tract such that the bisphosphonate is therapeutically effective. The ratio of bisphosphonate to modified amino acid carrier is from about 1:30 to about 1:1, respectively. These novel solid pharmaceutical dosage forms are useful in the treatment or control of bone diseases and particular disorders in calcium metabolism, including, for example, osteoporosis, hypercalcaemia of cancer, and the treatment of metastatic bone pain. The present invention also provides a method for treating these diseases employing the solid pharmaceutical dosage forms and a method for preparing the pharmaceutical dosage forms.

2013015, Jun 13, 2013

Feb 5, 2013

13/759348

Martin Howard Infeld - Upper Montclair NJ, US
Navnit Hargovindas Shah - Clifton NJ, US

Hoffmann-La Roche Inc. - Nutley NJ

A61K 31/522

51426331

The present invention provides novel solid pharmaceutical dosage forms for oral administration, after being constituted in water. The solid dosage forms comprise a therapeutically effective amount of valganciclovir hydrochloride and a non-hygroscopic organic acid present in an amount sufficient to stabilize the valganciclovir hydrochloride in a predetermined amount of water. The present invention also provides novel liquid pharmaceutical dosage forms for oral administration after constituting the solid pharmaceutical dosage form with water. A non-hygroscopic bulking agent may optionally be included in the above dosage form. These novel pharmaceutical dosage forms are useful in the treatment or control of viruses such as herpes simplex virus and cytomegalovirus. The present invention also provides a method for treating these diseases employing the solid and liquid pharmaceutical dosage forms and a method for preparing these pharmaceutical dosage forms.

2009028, Nov 12, 2009

Jul 16, 2009

12/504484

Hashim Ahmed - Princeton NJ, US
Lewis Bender - Redding CT, US
Martin Howard Infeld - Upper Montclair NJ, US
Shingai Majuru - Brewster NY, US
Wantanee Phuapradit - Montville NJ, US
Navnit Hargovindas Shah - Clifton NJ, US
Zhongshui Yu - Williston Park NY, US

Emisphere Technologies, Inc. - Cedar Knolls NJ

A61K 31/66

514108

The present invention provides novel solid pharmaceutical dosage forms for oral administration comprising a bisphosphonate, or a pharmaceutically acceptable salt thereof, which bisphosphonate is present in an amount not therapeutically effective when the bisphosphonate is orally administered alone, and a modified amino acid carrier, or a pharmaceutically acceptable salt thereof, which modified amino acid carrier is present in an amount effective to facilitate absorption of the bisphosphonate in the gastrointestinal tract such that the bisphosphonate is therapeutically effective. The ratio of bisphosphonate to modified amino acid carrier is from about 1:30 to about 1:1, respectively. These novel solid pharmaceutical dosage forms are useful in the treatment or control of bone diseases and particular disorders in calcium metabolism, including, for example, osteoporosis, hypercalcaemia of cancer, and the treatment of metastatic bone pain. The present invention also provides a method for treating these diseases employing the solid pharmaceutical dosage forms and a method for preparing the pharmaceutical dosage forms.

5036102, Jul 30, 1991

Sep 14, 1990

7/582467

Maria O. Bachynsky - Nutley NJ
Martin H. Infeld - Upper Montclair NJ
Richard J. Margolis - Wayne NJ
Dennis A. Perla - Wayne NJ

Hoffmann-La Roche Inc. - Nutley NJ

A61K 3135

514455

A method of treating leukocyte mediated autoimmune and skin diseases using psoralen reagent composition comprising sterile aqueous solutions suitable for extracorporeal administration to blood from a subject being treated by ultraviolet-A photophoresis.

2005000, Jan 13, 2005

Jul 8, 2004

10/886765

Antonio Albano - Clifton NJ, US
Martin Infeld - Upper Montclair NJ, US
Wantanee Phuapradit - Montville NJ, US
Navnit Shah - Clifton NJ, US
Lin Zhang - Bloomfield NJ, US

A61K031/551

514220000

A solid unit oral pharmaceutical dosage form of saquinavir mesylate is provided comprising micronized saquinavir mesylate in an amount of from 250 mg to 800 mg calculated as free base, and a pharmaceutically acceptable binder, disintegrant, and water soluble carrier. A solid unit dosage form of saquinavir mesylate is provided comprising from 60% to 80% micronized saquinavir mesylate based on the mesylate salt, 4% to 8% water soluble binder, a disintegrant and a carrier, wherein each percentage is of the kernel weight.

5190748, Mar 2, 1993

Dec 18, 1991

7/809244

Maria O. Bachynsky - Nutley NJ
Martin H. Infeld - Upper Montclair NJ
Navnit Shah - Clifton NJ
Joel Unowsky - Livingston NJ

Hoffmann-La Roche Inc. - Nutley NJ

A61K 3174

424 7808

The absorption of antibiotics given through oral and rectal routes of administration is significantly enhanced by use of the antibiotic in conjunction with a two-component absorption enhancing system made up of an ether of a C. sub. 6 to C. sub. 18 alcohol and a polyoxyethylene glycol together with a second component selected from among polyoxyethylene glycol C. sub. 6 to C. sub. 18 glyceride esters, C. sub. 6 to C. sub. 18 carboxylic acids or salts thereof, and esters of two or more C. sub. 6 to C. sub. 18 carboxylic acids, glycerol and a polyoxyethylene glycol. A carrier and adjuvants are usually included. These compositions can be administered in any convenient oral or rectal dosage form, including tablets, capsules, beadlets and suppositories.

2009005, Feb 26, 2009

Oct 31, 2008

12/262607

Antonio A. Albano - Clifton NJ, US
Martin Howard Infeld - Upper Montclair NJ, US
Wantanee Phuapradit - Montville NJ, US
Navnit Hargovindas Shah - Clifton NJ, US
Lin Zhang - Bloomfield NJ, US

A61K 31/4725

514307

A solid unit oral pharmaceutical dosage form of saquinavir mesylate is provided comprising micronized saquinavir mesylate in an amount of from 250 mg to 800 mg calculated as free base, and a pharmaceutically acceptable binder, disintegrant, and water soluble carrier. A solid unit dosage form of saquinavir mesylate is provided comprising from 60% to 80% micronized saquinavir mesylate based on the mesylate salt, 4% to 8% water soluble binder, a disintegrant and a carrier, wherein each percentage is of the kernel weight.

3989830, Nov 2, 1976

Aug 1, 1974

5/493955

Martin Howard Infeld - Montclair NJ
Harold Leon Newmark - Maplewood NJ

Hoffmann-La Roche Inc. - Nutley NJ

A61K 31555

424245

Stabilization of the copper II complex of 6-methoxy-1-phenazinol 5,10-dioxide, when used in a variety of dosage forms, is achieved by the addition of a 2-20% molar excess of copper ions to the specific dosage form.

2008008, Apr 10, 2008

Sep 25, 2007

11/860708

Maria Oksana Bachynsky - Nutley NJ, US
Martin Howard Infeld - Upper Montclair NJ, US
Mohammad Rashed - Randolph NJ, US
Navnit Hargovindas Shah - Clifton NJ, US

A61K 31/7064, A61K 9/30

424465, 514 49

There is provided a film coated pharmaceutical composition comprising 5′-deoxy-5-fluoro-N-[(pentyloxy)-carbonyl]-cytidine (capecitabine) and at least one disintegrant selected from the group comprising of crospovidone (particle size